Formula I Tyrosine Kinase Inhibitors with Segmented Aromatic Structure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for addressing unregulated tyrosine kinase signal transduction, which is involved in various disorders such as cancer and neurodegenerative diseases, lack effective inhibitors that can specifically modulate tyrosine kinase activity.
Innovation Solution
Development of novel compounds represented by Formula I, which can modulate, regulate, or inhibit tyrosine kinase signal transduction, comprising multiple aromatic components that act as protein tyrosine kinase inhibitors for treating diseases related to unregulated tyrosine kinase activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for addressing unregulated tyrosine kinase signal transduction are used, then existing treatments can be administered, but they lack effective inhibitors that can specifically modulate tyrosine kinase activity
Solution Approach 1:
The patent segments the tyrosine kinase inhibitor into multiple aromatic components (first aromatic component, second aromatic component, and third aromatic component) connected by linkers. This segmentation allows each component to contribute specifically to binding different regions of the tyrosine kinase enzyme, thereby achieving specific modulation while enabling systematic optimization of inhibitory activity.
Solution Approach 2:
The patent employs systematic variation of parameters including different aromatic rings (phenyl, naphthyl, heteroaryl), various linkers (alkylene, oxyalkylene, aminoalkylene), and multiple substituents (halo, alkyl, alkoxy, nitro, cyano) to optimize both the specificity and potency of tyrosine kinase inhibition. This parameter changes approach enables fine-tuning of the inhibitor's interaction with the kinase active site.
2Reliability
If novel compounds with multiple aromatic components are developed to specifically inhibit tyrosine kinase, then therapeutic efficacy for various disorders is improved, but the complexity of compound structure increases
Solution Approach 1:
The patent designs a universal multi-component aromatic structure that can target multiple tyrosine kinase isoforms and subtypes (including EGFR, HER2, PDGFR, FGFR, and VEGFR) through systematic substitution patterns. The core tricyclic framework with variable linkers and substituents provides a multi-functional platform that maintains structural consistency while achieving broad therapeutic applicability across different disorders.
Solution Approach 2:
The patent employs a nested structural organization where three aromatic components are hierarchically arranged with specific linkers connecting them in sequence. The first aromatic component connects to the second via a first linker, and the second connects to the third via a second linker, creating a nested configuration that optimizes spatial arrangement for enzyme binding while maintaining manageable structural complexity through modular design.
Data Source
AI summary
The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.